RT Journal Article
SR Electronic
T1 Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70, Lyon, France, August to December 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20228528
DO 10.1101/2020.11.10.20228528
A1 Bal, Antonin
A1 Destras, Gregory
A1 Gaymard, Alexandre
A1 Regue, Hadrien
A1 Semanas, Quentin
A1 d’Aubarede, Constance
A1 Billaud, Geneviève
A1 Laurent, Frédéric
A1 Gonzalez, Claudia
A1 Valette, Martine
A1 Bouscambert, Maude
A1 Lina, Bruno
A1 Morfin, Florence
A1 Josset, Laurence
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/12/24/2020.11.10.20228528.abstract
AB The spike deletion H69-V70 (ΔH69/ΔV70) has been recently detected in a SARS-CoV-2 variant under investigation in England (VUI 202012/01) as well as in cluter-5 variant detected both in minks and humans in Denmark. Herein we report the implementation of a two-step strategy enabling to detect SARS-CoV-2 variants carrying H69-V70 deletion. We found that this deletion resulted in a false negative result for the spike target of a three-target RT-PCR assay (TaqPath kit). From August 3rd to December 20th, 59/9,266 (0.6%) of positive tests displayed a S negative profile (negative for S target and positive for N & ORF1ab targets). Among the 59 samples without detection of the S target, 36 were available for whole genome sequencing (WGS). The most frequent S mutations co-occurring with ΔH69/ΔV70 were S477N & D614G (21/36 samples). The co-occurrence of N439K and D614G mutations was found in 10/36 samples. The complete combination of S mutations detected in VUI 202012/01 or in cluster-5 variant was not found. The data presented herein emphasize that the TaqPath RT-PCR assay enables a rapid, large-scale screening of ΔH69/ΔV70 variants. Samples with S negative profiles should be further addressed to national referral laboratories for SARS-CoV-2 WGS. This 2-step strategy is currently being reinforced in France as national diagnostic platforms have mainly implemented the TaqPath RT-PCR kit.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSamples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41).Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was approved by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genomes sequenced in this study were deposited in the GISAID database (EPI_ISL_582110, EPI_ISL_582111, EPI_ISL_582112, EPI_ISL_582113, EPI_ISL_582114, EPI_ISL_582115, EPI_ISL_582116, EPI_ISL_582117, EPI_ISL_582118, EPI_ISL_582119, EPI_ISL_582120, EPI_ISL_582508, EPI_ISL_623098, EPI_ISL_623099, EPI_ISL_623100, EPI_ISL_623101, EPI_ISL_623102)